The Clinical and Laboratory Standards Institute (CLSI) recently abandoned its recommendation for drawing a discard tube when performing a prothrombin time (PT)/international normalized ratio (INR) or an activated partial thromboplastin time (APTT)
Preanalytic variables may affect test results. In particular, coagulation assays are sensitive to variation in conditions during the collection, transport, and processing of blood specimens. During the last few years, there has been much debate whether a discard tube should be drawn for plasma-based coagulation assays when using a standard evacuated tube collection system. The rationale for a discard tube is based on historic coagulation testing using the whole blood clotting time, in which tissue thromboplastin released and activated during venipuncture could lead to erroneous results. A few studies have already shown that with today's coagulation reagents and venipuncture procedures, using extremely sharp low-resistance needles, a discard tube is not necessary for prothrombin time (PT) and activated partial thromboplastin time (APTT). [1] [2] [3] [4] Because of these studies, the Clinical and Laboratory Standards Institute (CLSI), formerly known as National Committee for Clinical Laboratory Standards, has abandoned the recommendation for a discard tube for PT/ international normalized ratio and APTT testing in its latest guideline, H21-A5. 5 Because there is no proof of the necessity that a discard tube should be drawn for other, more specialized coagulation assays, the CLSI was not able to report a recommendation for these assays. Therefore, the aim of this study was to determine whether drawing a discard tube for several plasma-based specialized coagulation assays is required.
Materials and Methods

Patient Recruitment and Methods
From October until December 2007, 88 consecutive patients, for whom coagulation tests were requested, were asked to participate in the study. By Dutch law, ethical approval is not needed for studies in which samples are anonymously used for quality enhancement or evaluation protocols of clinical chemistry assays unless the patient refuses that his or her sample be used for this purpose. To be sure that each patient had no objection, we obtained written informed consent. To be able to investigate the whole concentration range of coagulation factors and their inhibitors, subjects were recruited from several subpopulations, including 30 random control subjects (for concentrations in the normal range), 30 patients receiving coumarin therapy, 13 patients with hemophilia A or B, and 15 subjects suspected of having a bleeding disorder.
From each subject, blood was consecutively drawn into 2 labeled 5-mL plastic evacuated tubes (tube 1 and tube 2) containing 0.109 mol/L trisodium citrate (BD Vacutainer, Becton Dickinson, Plymouth, England) by venipuncture. Each tube was filled with 4.5 mL of blood and 0.5 mL of buffered citrate solution (ie, 9:1 blood/buffer ratio). If other blood tests were ordered, tubes for these were drawn after the duplicate citrated tubes for the study. The sampling procedure was performed according to the guidelines of the European Concerted Action on Thrombosis and Disabilities. 6 In short, blood was drawn using a 21-gauge needle with minimal tourniquet application to prevent stasis and was immediately mixed by gently inverting the tube 5 times. The sample was centrifuged within 30 minutes at 2,500g and 20°C for 15 minutes without brake. Plasma was carefully removed and transferred to a nonactivating centrifuge tube using a plastic pipette and was centrifuged again using the same conditions. Platelet-free plasma was divided into aliquots and stored at -80°C until analysis. Just before analysis, frozen samples were rapidly thawed at 37°C for 5 minutes. For each parameter, tube 1 and tube 2 were analyzed consecutively within the same run.
Parameters were tested using the Advance Coagulation analyzer (Instrumentation Laboratory, Breda, the Netherlands), according to the instructions of the manufacturer. Reagents and factor-deficient plasma used for each parameter are listed in ❚Table 1❚ 7, 8 and were obtained from Instrumentation Laboratory. In short; APTT and PT were measured using optical clot detection, individual coagulation factors using a 1-stage PT assay (factors II, V, and X) or a 1-stage APTT assay (factors VIII and IX), antithrombin using a factor Xa-based assay, and protein C using a chromogenic substrate-based assay in which its amidolytic activity is assessed after a snake venom activation.
Statistical Analysis
Data were evaluated statistically using Microsoft Excel 2003 software (Microsoft, Redmond, WA) and Analyse-It, version 1.72 (Analyse-It Software, Leeds, England). Because data were not normally distributed, the differences between tubes 1 and 2 were tested using the Wilcoxon signed rank test for paired samples. To correct for multiple testing, a Bonferroni correction was used, and a P value less than .006 was considered significant. 9 The agreement between the sampling methods was investigated by using Passing-Bablok method comparison, and individual bias with 95% limits of agreement between paired samples was assessed by using Bland-Altman analysis. If a statistically significant difference was found, the clinical significance of this finding was evaluated by using the maximal difference (10%) between individual samples as reported by the CLSI and the critical difference (d K ), a mathematical approach that shows the 95% range of all differences between 2 subsequently obtained values in a healthy person and is defined as 2√2 * √(CV P 2 + CV A 2 ), 8 with CV P the intraindividual coefficient of variation and CV A the analytic coefficient of variation. For each coagulation parameter, the d K , CV p , and CV A as assessed in our laboratory are given in Table 1 .
Results
The results for the coagulation assays investigated are summarized in ❚Figure 1❚ and ❚Table 2❚. Of the routine APTT, activated partial thromboplastin time; CV, coefficient of variation; PT, prothrombin time. * All reagents were purchased from Instrumentation Laboratory (Breda, the Netherlands). † Intrasubject CVs for APTT, PT, antithrombin, and protein C derived from Wada et al 7 and for factors V and X from Costongs et al. 8 Intrasubject CVs for factors II, VIII, and IX are estimates based on the reported values for factors V and X (average). ‡ Intra-assay CVs were determined by repeated measurement (n = 10) of a plasma pool at our laboratory. CI, confidence interval. * Passing-Bablok method comparison was used to test for agreement between both methods of sampling; x = tube 2 ("gold standard" method), and y = tube 1 (method under investigation). Bland-Altman bias plots were generated to investigate bias for individual samples. Statistical differences in values between sampling methods (tube 2 vs tube 1) were investigated using the Wilcoxon signed rank test for paired samples.
Mean of APTT (s)
coagulation assays tested, only the APTT showed a significant difference in clotting time between sampling methods (tube 2 vs tube 1) with a mean prolongation of the APTT of 0.5 seconds (P = .001) in tube 1. However, the individual bias of paired samples (range, -6.5% to 8.8%) remained lower than the critical difference. For the PT, no statistically significant difference was found between the samples, and individual bias (range, -3.7% to 4.7%) was lower than the calculated critical difference. For the specialized coagulation assays, differences between the sampling methods were found for antithrombin and protein C. For antithrombin, the mean concentration in tube 1 was 0.7 U/dL lower than in tube 2 (P = .002). PassingBablok analyses showed good agreement between sampling methods with a slope of the regression equation of 1. The individual bias of the paired samples (range, -6.2% to 6.3%) remained within the critical difference. For protein C, the mean concentration in tube 1 was 0.8 U/dL lower than in tube 2 (P < .0001), and the Passing-Bablok regression equation showed a proportional bias in the slope. However, the individual bias of the paired samples (range, -8.2% to 3.3%) remained within the critical difference.
All other specialized coagulation assays tested showed no statistically significant differences in measured values between sampling methods, and bias of the paired samples was lower than the critical difference. Ranges for the relative differences between tubes 1 and 2 were as follows: factor II, -12.1% to 8%; factor V, -10.0% to 11.1%; factor VIII, -15.4% to 9.0%; factor IX, -9.8% to 10.7%; and factor X, -11.0% to 11.8%.
Discussion
In this study, we have shown small, statistically significant but not clinically relevant differences between the discard tube and the second tube for 3 assays. These data imply that drawing a discard tube is not necessary for routine and certain specialized coagulation assays. Although we have not tested this for all coagulation factors and inhibitors, we have no reason to expect that this conclusion does not apply to coagulation factors VII, XI, and XII and protein S, especially because there is no proof that says otherwise.
The findings for the routine coagulation parameters (PT and APTT) are in line with those previously reported, [1] [2] [3] [4] 10 with a mean and maximum difference for the PT measurement between tubes that are comparable to those found by Yawn et al 1 (mean, 0.05 second; maximum, 3.8 seconds) and Gottfried and Adachi 3 (mean, 0.1 second; maximum, 3.8 seconds). In the latter study, the APTT also was measured, and regression analysis was performed. For the APTT, the mean difference (0.48 second) was equal to that found in our study.
The maximal difference (32.2 seconds), however, was worse compared with that in our study. The equations of the regression lines were also comparable. 3 A limitation of the study is that critical differences were calculated using intra-assay CVs determined by our laboratory and intersubject CVs derived from the literature. This may have resulted in critical differences that are not completely valid for our population. Most important, nearly all individual relative differences remained below the maximum of 10% as recommended by the CLSI. For all samples with results above this maximal difference, the clinical relevance was investigated, and it was found that none were clinically relevant ❚Table 3❚. For the determination of the range of relative differences, 1 sample for factor II and 1 for factor VIII were excluded (43.5% and 19.0% differences, respectively). In all other statistical tests, however, these samples (sample IDs 59 and 82) have been included. In box-whisker plots (data not shown), these samples are identified as far outliers, but the absolute differences are not clinically relevant. Inclusion of these samples would have led to a range of relative differences that, in our opinion, does not give a good representation of reality.
The previous CLSI guideline advocating a discard tube was based on the hypothesis and circumstantial proof at best that the tissue thromboplastin released at venipuncture will contaminate the first tube drawn, thereby activating the clotting cascade. 1 prolongation of the APTT in tube 1 as compared with tube 2. Although statistically significant, this difference was not clinically relevant. The decreases that were found for the individual clotting factors, with the largest decrease found for factor VIII, were too small to be statistically or clinically relevant. Moreover, the individual bias between samples was generally smaller than the critical difference for each assay calculated using the in-house laboratory variance (Table 1) . However, according to CLSI guidelines, a 10% difference between samples is acceptable and differences of more than 10% are said to be of clinical relevance. Most samples fulfilled these criteria, but a few individual samples did not, and these samples were evaluated in more detail (Table 3 ). It was noticed that based on the differences between reported values for tubes 1 and 2, clinical diagnosis would not have been affected. Especially at low levels, small absolute differences may result in a large bias when this is expressed as a percentage to the mean of both values. For example, the difference of 43.5% between one sample of factor II results from an absolute bias of 5 U/dL at a level of around 10 U/dL (14 vs 9 U/dL). Values of either tube 1 or tube 2 would have led to the same conclusion: the patient has factor II deficiency. The findings of our study support the new CLSI guideline that a discard tube is unnecessary for routine coagulation assays and provide evidence that drawing a discard tube can also be abandoned for certain plasma-based specialized coagulation tests. 
